These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 16019756)

  • 1. Prognostic and predictive factors in prostate cancer: historical perspectives and recent international consensus initiatives.
    Srigley JR; Amin M; Boccon-Gibod L; Egevad L; Epstein JI; Humphrey PA; Mikuz G; Newling D; Nilsson S; Sakr W; Wheeler TM; Montironi R
    Scand J Urol Nephrol Suppl; 2005 May; (216):8-19. PubMed ID: 16019756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
    Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
    J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of serum markers for prostate cancer.
    Stenman UH; Abrahamsson PA; Aus G; Lilja H; Bangma C; Hamdy FC; Boccon-Gibod L; Ekman P
    Scand J Urol Nephrol Suppl; 2005 May; (216):64-81. PubMed ID: 16019759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive factors in prostate cancer: current concepts from the 1999 College of American Pathologists Conference on Solid Tumor Prognostic Factors and the 1999 World Health Organization Second International Consultation on Prostate Cancer.
    Bostwick DG; Foster CS
    Semin Urol Oncol; 1999 Nov; 17(4):222-72. PubMed ID: 10632123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prognostic factors of localised, locally advanced or metastatic prostate cancer].
    Joly F; Henry-Amar M
    Bull Cancer; 2007 Jul; 94(7 Suppl):F35-43. PubMed ID: 17845992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate-specific antigen doubling time as a prognostic marker in prostate cancer.
    Eastham JA
    Nat Clin Pract Urol; 2005 Oct; 2(10):482-91. PubMed ID: 16474622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prognostic factors in prostate cancer. Review of the literature and future perspectives].
    Cussenot O; Ravery V; Desgrandchamps F; Cochand-Priollet B; Teillac P; Le Duc A
    Prog Urol; 1994 Feb; 4(1):17-30. PubMed ID: 7514473
    [No Abstract]   [Full Text] [Related]  

  • 8. [Markers for diagnosis, prediction and prognosis of prostate cancer].
    Taskén KA; Angelsen A; Svindland A; Eide T; Berge V; Wahlquist R; Karlsen S
    Tidsskr Nor Laegeforen; 2005 Dec; 125(23):3279-82. PubMed ID: 16327854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidemiology and statistical methods in prediction of patient outcome.
    Bostwick DG; Adolfsson J; Burke HB; Damber JE; Huland H; Pavone-Macaluso M; Waters DJ
    Scand J Urol Nephrol Suppl; 2005 May; (216):94-110. PubMed ID: 16019761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lead time of prostate cancer detected in population based screening for prostate cancer in Japan.
    Ito K; Yamamoto T; Miyakubo M; Takechi H; Ohi M; Shibata Y; Suzuki K
    J Urol; 2007 Oct; 178(4 Pt 1):1258-63; discussion 1263-4. PubMed ID: 17698107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biomarkers in prostate cancer diagnosis and prognosis: beyond prostate-specific antigen.
    Fradet Y
    Curr Opin Urol; 2009 May; 19(3):243-6. PubMed ID: 19325493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using spectral moments of spiral networks based on PSA/mass spectra outcomes to derive quantitative proteome-disease relationships (QPDRs) and predicting prostate cancer.
    Ferino G; González-Díaz H; Delogu G; Podda G; Uriarte E
    Biochem Biophys Res Commun; 2008 Jul; 372(2):320-5. PubMed ID: 18503754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prognosis and predictive factors in prostate cancer].
    Albiges-Sauvin L; Lévy A; Massard C; Fizazi K
    Bull Cancer; 2009 Apr; 96(4):439-49. PubMed ID: 19357018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Re: The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?
    Rosser CJ; Parker A
    J Urol; 2005 Sep; 174(3):1154-5; author reply 1155-6. PubMed ID: 16094093
    [No Abstract]   [Full Text] [Related]  

  • 15. The biology of prostate cancer: new and future directions in predicting tumor behavior.
    Partin AW; Carter HB; Epstein JI; Coffey DS
    Monogr Pathol; 1992; (34):198-218. PubMed ID: 1406742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New molecular biomarkers for the prognosis and management of prostate cancer--the post PSA era.
    Bickers B; Aukim-Hastie C
    Anticancer Res; 2009 Aug; 29(8):3289-98. PubMed ID: 19661347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate-specific antigen/prostatic acid phosphatase ratio is significant prognostic factor in patients with stage IV prostate cancer.
    Saito T; Hara N; Kitamura Y; Komatsubara S
    Urology; 2007 Oct; 70(4):702-5. PubMed ID: 17991541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. College of American Pathologists Conference XXVI on clinical relevance of prognostic markers in solid tumors. Report of the Prostate Cancer Working Group.
    Grignon DJ; Hammond EH
    Arch Pathol Lab Med; 1995 Dec; 119(12):1122-6. PubMed ID: 7503660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of the 2005 international society of urological pathology consensus conference on standard Gleason grading of prostatic carcinoma in needle biopsies.
    Billis A; Guimaraes MS; Freitas LL; Meirelles L; Magna LA; Ferreira U
    J Urol; 2008 Aug; 180(2):548-52; discussion 552-3. PubMed ID: 18550106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pretreatment serum level of HER2/nue as a prognostic factor in metastatic prostate cancer patients about to undergo endocrine therapy.
    Okegawa T; Kinjo M; Nutahara K; Higashihara E
    Int J Urol; 2006 Sep; 13(9):1197-201. PubMed ID: 16984552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.